Table 1.

Baseline demographic and anthropometric characteristics of randomized patients

	Omarigliptin	Sitagliptin	Placebo
	N = 166	N = 165	N = 83
Age, years	60 ± 11	60 ± 9	61 ± 9
Male, n (%)	104 (62.7)	115 (69.7)	57 (68.7)
Body Weight, kg	67 ± 13	69 ± 14	64 ± 12
BMI, kg/m2	25.2 ± 3.7	25.4 ± 4.2	24.3 ± 3.3
Duration of T2D, years	7.4 ± 5.5	7.4 ± 5.3	8.6 ± 5.1
Prior AHA use, n (%)	65 (39.2)	61 (37.0)	32 (38.6)
HbA1c, %	7.9 ± 0.7	8.0 ± 0.8	8.1 ± 0.7
Range	6.9‐9.9	6.7‐9.9	6.9‐10.0
2‐hour PPG, mmol/L	13.4 ± 3.5	13.4 ± 3.7	13.7 ± 3.3
FPG, mmol/L	9.0 ± 1.7	8.8 ± 1.7	9.0 ± 1.6

Abbreviation: BMI, body mass index.

Values are mean ± standard deviation, unless otherwise indicated.